What's Next in the Triple Agonist Research Pipeline Beyond retatrutide, other triple agonist candidates are in earlier-stage clinical development
While the level of evidence for each compound varies, all of them lack the kind of large, well-controlled trials in humans that are necessary to establish safety and effectiveness, which is required for drug approvals
Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice
If you observe any side effects, consult your healthcare provider immediately
Yes, virtual ticket holders will get access to attend live via zoom as well as receive copies of all the slides, content, protocols, consent forms and everything else the in-person attendees will receive